The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...

The brain drug developer is continuing a trial despite a recommendation it be stopped for futility. Elsewhere, Eli Lilly ...

While announcing billions of dollars in new U.S. investments, David Ricks called for an extension of 2017 tax cuts and ...

The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...

The meeting, which helps the FDA give guidance to vaccine makers on which flu strains to target, is the second to be ...

Cavazzoni stepped down from her role as head of the FDA’s main drug review office in mid-January. She will succeed Aida ...

An industry source said “most, if not all” of the people at CDRH who were recently dismissed are now being asked to return.

The funding comes as Eikon, run by former Merck research chief Roger Perlmutter, has started a Phase 3 trial testing one of ...

Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...

Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” ...

The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...

The British drugmaker claimed success in a first-line breast cancer study. Elsewhere, Rezdiffra sales continued to grow and a ...